These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 20797824

  • 21. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H, Bissonette EA, Theodorescu D.
    Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK.
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: a preliminary report.
    Sasaki T, Nakamura K, Shioyama Y, Ohga S, Urashima Y, Terashima H, Koga H, Naito S, Noma H, Komatsu K, Yamaguchi A, Honda H.
    Jpn J Clin Oncol; 2004 Jul; 34(7):420-4. PubMed ID: 15342670
    [Abstract] [Full Text] [Related]

  • 24. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):23-30. PubMed ID: 19395187
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ, Marion C, Fuks Z, Leibel SA.
    J Urol; 2003 Nov 01; 170(5):1828-32. PubMed ID: 14532785
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW.
    Cancer; 2002 Jul 15; 95(2):275-80. PubMed ID: 12124826
    [Abstract] [Full Text] [Related]

  • 33. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 34. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
    Jani AB, Basu A, Abdalla I, Connell PP, Krauz L, Vijayakumar S.
    Am J Clin Oncol; 2003 Aug 01; 26(4):382-5. PubMed ID: 12902891
    [Abstract] [Full Text] [Related]

  • 35. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 36. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
    Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.
    J BUON; 2009 Nov 01; 14(4):629-34. PubMed ID: 20148454
    [Abstract] [Full Text] [Related]

  • 37. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.
    Lancet Oncol; 2014 Sep 01; 15(10):1076-89. PubMed ID: 25130995
    [Abstract] [Full Text] [Related]

  • 38. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 39. The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).
    Daly PE, Dunne MT, O'Shea CM, Finn MA, Armstrong JG.
    Radiother Oncol; 2012 Jul 15; 104(1):96-102. PubMed ID: 22682750
    [Abstract] [Full Text] [Related]

  • 40. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM, Bishop DC, Pai H, Eldridge B, Lim J, Berthelet E, Blood P, Piercy GB, Steinhoff G.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1309-15. PubMed ID: 16029786
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.